

Title: Contribution to malaria transmission of symptomatic and asymptomatic parasite carriers in Cambodia

Running title: Malaria transmission in Cambodia

Amélie Vantaux^{1*}, Reingsey Samreth¹, Eak Por Piv¹, Nimol Khim¹, Saorin Kim¹, Laura Berne^{1,2},
Sophy Chy¹, Dysoley Lek^{3,4}, Sovannaroeth Siv⁴, Walter R. Taylor^{5,6} and Didier Ménard^{1,7}

¹ Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom Penh, Cambodia

² Xeno Cell Innovations, Plzen, Czech Republic

³ National Center for Parasitology, Entomology and Malaria Control Program, Phnom Penh, Cambodia

⁴ School of Public Health, National Institute of Public health, Cambodia

⁵ Mahidol Oxford Tropical Medicine Research Unit (MORU), Mahidol University, Bangkok, Thailand

⁶ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

⁷ Unité Biologie des Interactions Hôte-Parasite, Institut Pasteur, Paris, France

* corresponding author: avantaux@pasteur-kh.org

40 word summary: Falciparum malaria infectivity was relatively low in patients (~6%, 3/48).

None of the falciparum (0/19) and 3/28 vivax asymptomatic carriers were infectious to mosquitoes, including those followed up for two months. Overall infectivity of falciparum carrier is low in Cambodia.

Word count abstract: 200

Word count text: 3498

Abstract

Background: Eliminating falciparum malaria in Cambodia is a top priority, requiring the implementation of novel tools and strategies to interrupt its transmission. To date, few data are available regarding the contributions to malaria transmission of symptomatic and asymptomatic carriers.

Methods: Direct-membrane and skin feeding assays (DMFA, SFA) were performed, using *Anopheles minimus* and *An. dirus*, to determine infectivity of symptomatic falciparum-infected patients and malaria asymptomatic carriers; a subset of the latter were followed for two months to assess their transmission potential.

Results: By microscopy and RT-PCR, *P. falciparum* gametocyte prevalence rates were, respectively, 19.3% (21/109) and 44% (47/109) on Day (D) 0 and 17.9% (5/28) and 89.3% (25/28) in recrudescence patients (Drec) (RT-PCR Drec vs. D0 $P=0.0015$). Falciparum malaria patient infectivity was low on D0, 6.2% (3/48), and Drec, 8.3% (1/12). DFMA and SFA gave similar results. None of the falciparum (0/19) and 3/28 *P. vivax* asymptomatic carriers were infectious to mosquitoes, including those that were followed up for two months. Overall, *P. falciparum* gametocytemias were low except in a few symptomatic carriers.

Conclusions: Only symptomatic falciparum malaria patients were infectious to mosquito vectors at baseline and recrudescence, highlighting the need to detect promptly and treat effectively *P. falciparum* patients.

Key words (3-10): malaria, elimination, *P. falciparum*, *P. vivax*, infectivity, transmission, gametocytes, *Anopheles*, low-transmission setting, Cambodia

Background

Over the last decade, the global malaria burden has decreased markedly due to concerted international efforts on improving malaria control. However, this disease remains a major public health challenge with an estimated 212 million cases recorded in 2015 [1]. In Southeast Asia, the burden of *Plasmodium falciparum* malaria has followed the same trend, despite the emergence of artemisinin- and partner drug resistance, a major threat that could reverse the current global achievement in malaria control [2-5]. Consequently, eliminating *P. falciparum* malaria is a top priority for the Cambodian government and international organizations. However, moving towards malaria elimination, requires implementing novel tools and strategies that specifically aim at interrupting malaria transmission like the introduction of single low dose primaquine, advocated by the WHO in 2012 [6]. Developing such effective tools relies on understanding the nature of malaria transmission in Cambodia, knowing the who, when and where of parasite transmission to mosquito vectors and assessing the contribution to malaria transmission of symptomatic malaria cases and asymptomatic parasite carriers.

Human-to-mosquito transmission is mediated by gametocytes, which are ingested by mosquitoes taking a blood meal from malaria infected individuals. To assess malaria parasite carrier infectivity, mosquito feeding assays are considered the gold standard [7, 8]. Gametocytaemia is strongly correlated to infectivity in a nonlinear relationship but this association may vary according to the seasonality and the epidemiological context [9, 10]. For instance, individuals with high gametocytaemia do not always lead to high mosquito infection rates whereas individuals with submicroscopic gametocytaemia may infect mosquitoes [11-13].

To date, few studies have investigated the infectivity of malaria parasite carriers in Southeast Asia and human-to-mosquito transmission from symptomatic or asymptomatic *Plasmodium* infected

individuals remains unclear. For vivax malaria infections, it has been shown that symptomatic carriers are highly infectious with 58% to 84% of patients infecting mosquito vectors [14-16] but this falls to 0% to 13.5% for asymptomatic vivax carriers [11, 16]. For *P. falciparum*, infectivity appears much lower, both in symptomatic Cambodian (5.9% [17]) and Thai patients (>25% [15]) and in asymptomatic Thai carriers (10% [11]).

Limited data suggest that the major source of malaria transmission in Southeast Asia appears to be *P. falciparum* symptomatic carriers who have patent gametocytemia (96% of all mosquito infections [17]). However, data on the infectivity of submicroscopic carriers over time are lacking and no comprehensive studies comparing symptomatic and asymptomatic malaria parasite carriers of both main species have been carried out in Cambodia. Therefore, we assessed the infectivity of patients with uncomplicated falciparum malaria seeking treatment and asymptomatic carriers in the dry and the rainy seasons.

Methods

Symptomatic patients study

An open-label randomised control trial assessing the tolerability and the safety of a single low dose primaquine (SLDPQ) was carried out in Banlung, Rattanakiri province in 2015-2016 (NCT02434952). Rattanakiri province is located in the northeast of Cambodia and is sparsely populated. Residents generally live in villages of 20 to 60 families. The two main malaria vector species are *Anopheles minimus* and *Anopheles dirus* [18, 19].

Briefly, nonpregnant, nonbreast feeding patients aged ≥ 1 year with acute uncomplicated falciparum malaria (≥ 1 asexual parasite/500 white blood cells) and a haemoglobin concentration

≥6g/dL were recruited to receive either dihydroartemisinin-piperaquine (DHA-PP, Duo-Cotecxin®, DHA40 mg and PP320 mg, Zhejiang Holley Nanhu Pharmaceutical Co. Ltd, Jiaxing, Zhejiang province, China) alone or combined with SLDPQ (0.25mg/kg given with the first dose of DHA-PP, Thai Government Pharmaceutical Organization, 15mg base primaquine tablet). Clinical and laboratory assessments were performed on Days (D) 0, 1, 2, 3, 7, 14, 21 and 28. *Anopheles minimus* mosquitoes were fed on D0 blood samples collected from a subset of patients and on the first day of recurrent (Drec) falciparum parasitaemia (defined by the WHO as late treatment failure) depending on mosquito availability using direct-membrane feeding assays (DMFA; Figure 1).

An additional cohort of symptomatic *P. falciparum* mono-infection patients were recruited later in 2016 from villages or the local health centers in the same province. Both *An. minimus* and *An. dirus* mosquitoes were fed directly on patient's skin (skin-feeding assays, SFA) and on blood samples collected on D0 before artesunate-mefloquine treatment (DMFA; Figure 1).

Asymptomatic malaria infection studies

Follow-up in the dry season. In January 2016, participants were screened in Kam village (Laork commune, Ohchum district, Rattanakiri province, Fig.S1). All nonpregnant, nonbreast feeding persons aged >5 year and who did not receive a malaria treatment in the last 4 weeks were invited to participate in the study. *Plasmodium* species were detected by real-time polymerase chain reaction (RT-PCR) on filter paper blood spots and symptomatic malaria positive participants were treated according to national guidelines. All asymptomatic malaria carriers (temperature<37.5°C) and three malaria-free individuals were enrolled for DMFA (*An. dirus*) and were screened for malaria by RT-PCR on whole blood sample on the first week (Figure 1). Among them, seventeen

asymptomatic participants (all *P. falciparum* and mixed *P. falciparum/P. vivax* carriers and one randomly selected *P. vivax* carrier participants from week 0) were enrolled for an additional seven weeks follow-up. DMFA and gametocyte detection were carried out weekly in the first month and then every two weeks in the second month. All participants who became symptomatic were immediately treated and excluded from further follow-up.

Follow-up in the rainy season. In August 2016, volunteer participants from the same village (Kam village) and three additional villages (Ohlang, Kres and Tangach villages, Poy commune; Figure S1) were screened. A total of 26 asymptomatic (all *P. falciparum*, mixed *P. falciparum/P. vivax* and *P. malariae* cases and fifteen randomly selected *P. vivax* participants from week 0) were included and followed-up for two months with the same protocol.

Entomological investigations

DMFAs were carried out to assess individual malaria infectivity. Briefly, 6-to-8-day-old *An. dirus* or 3-to-5-day-old *An. minimus* females were fed through membranes on patient's blood. Mosquitoes were starved for 24h before being provided a blood meal. Venous blood samples were collected in heparinized tubes and 400µl of blood were made available in membrane feeders maintained at 37°C. Females were fed only once on freshly drawn blood. SFAs were carried out by allowing females to feed for 20 minutes on patient skin using the forearm. Post-feeding, unfed females were discarded and fed females were kept in cages (20x20x20cm) with constant access to a 10% sucrose solution. Patient infectivity was determined by assessing infection prevalence (i.e. proportion of infected mosquitoes) and infection intensity (i.e. number of *Plasmodium sp.* oocysts in infected females). Midguts were dissected in a 1% Mercurochrome® stain and the presence and the number of oocysts were determined under a microscope (20x magnification). Dissections were

performed 7 days post-blood meal. A median number of 50 females was dissected in all assays (DMFA and SFA).

Biological investigations

Sexual and asexual parasite counts (D0 and follow-up days) were determined on Giemsa-stained thick films and recorded as the number of parasites per 500 white blood cells (assuming a white blood cell count of 8000/ μ L). Two qualified microscopists read the slides and parasite densities were recorded as the average of these two counts. A third reading was conducted if the discrepancy between parasite densities exceeded 30%.

Parasite DNA was extracted from filter paper blood spots or 200 μ l whole blood with Instagene[®] Matrix (Bio-Rad, Courtaboeuf, France) or DNA Blood Mini kit[®] (Qiagen, Germany), according to the manufacturer's instructions. Parasite RNA was extracted from the Trizol[®] (Life Technologies Holdings Pte Ltd, Singapore) conserved whole blood samples using QIAamp RNA Blood Mini Kit[®] (Qiagen, Germany), following manufacturer's protocol.

A two-step semiquantitative RT-PCR was performed to detect malaria parasites, as previously described [20]. Following PCR amplification, falciparum positive samples were analyzed for the presence of gametocytes by a Taqman RT-PCR, using primers spanning an exon-exon junction and targeting the "*Plasmodium falciparum* meiotic recombination protein DMC1-like protein" gene (AF356553), as in [21]. Gametocyte dilution series based on *in-vitro* cultured local strain were used to estimate gametocyte blood concentrations.

P. falciparum positive samples were screened for mutations in the K13-propeller domain gene, associated with artemisinin resistance [22]. PCR products were sequenced by Macrogen (Seoul,

Korea) and electropherograms were analyzed on both strands, using PF3D7_1343700 as the reference sequence. *P. falciparum* bar-coding assays were performed as per Daniels *et al* with minor modifications [23]. Polymorphisms in twelve SNPs were assessed by nested PCR approach. PCR LDR-FMA (PCR-Ligase Detection Reaction-Fluorescence Microspheres Assay) reactions were used to define a molecular barcode for each isolate [24].

The capillary electrophoresis (MINICAP system™, Sebia, France) and the quantitative determination of G6PD activity (Trinity Biotech quantitative G6PD assay™, Ref 345-UV, Trinity Biotech, USA) were carried out on blood collected from symptomatic patients. Haemoglobin disorders were classified as in [25].

Statistical analyses

Groups were compared using the Chi squared test, Fisher's exact test, McNemar test, or Wilcoxon test, as appropriate. For data from D0 samples, binomial general linear models (GLMs) were fitted to investigate gametocyte prevalence estimated by RT-PCR. In these models, sex, G6PD phenotype, haemoglobinopathies, age, seasonality (dry *vs.* rainy season), K13 mutation (mutant *vs.* wild-type alleles) and clinical outcome (cured *vs.* PCR-corrected recrudescence) were coded as fixed factors. Infection prevalence determined with DMFA only was assessed using binomial generalized linear mixed models (GLMMs) to compare symptomatic and asymptomatic carriers. In this model, clinical status (asymptomatic *vs.* symptomatic) was coded as a fixed factor, individual was coded as a random factor to account for repeated measures on the same parasite carrier and an observation-level random effect was added to account for over dispersion. Infection prevalence was also compared on the subset of *P. falciparum* symptomatic and asymptomatic carriers only, using a similar GLMM. For model selection, we used the stepwise removal of terms,

followed by likelihood ratio tests. Term removals that significantly reduced explanatory power ($P < 0.05$) were retained in the minimal adequate model [26]. All analyses were performed in R v.3.0.3.

Ethical statement

Ethical approvals were obtained from the Cambodian National Ethics Committee for Health Research (0370NECHR, 197NECHR, 319NECHR). The protocols conformed to the Helsinki Declaration on ethical principles for medical research involving human subjects (version 2002) and informed written consent was obtained for all volunteers.

Results

*Contribution to malaria transmission of *P. falciparum* symptomatic patients*

One hundred and nine patients with uncomplicated falciparum malaria were enrolled in the study and treated with standard 3-day DHA-PP alone (48%, 53/109) or DHA-PP plus SLDPQ (52%, 56/109). Seven patients were lost to follow up (6%). The cumulative proportion of *P. falciparum* PCR-corrected recrudescence among patients who completed the follow-up was 27.4% (28/102). Of the 28 recrudescence patients, 10 were retreated with the standard 3-day DHA-PP and the remainder with quinine or quinine plus tetracycline; six of the 10 patients retreated with DHA-PP experienced a second recrudescence.

At D0, gametocytes were detected in 21/109 patients (19.3%, median=39 gametocytes/ μ l, range: 16-1432 gametocytes/ μ l) by microscopy and in 47/109 patients (44 %) by RT-PCR. Blood samples

from 48 patients were fed to mosquitoes and 3 patients with patent gametocytes (6.2%) were infectious to mosquitoes (Table 1, Table S1). Gametocyte prevalence by RT-PCR was not significantly different between the patients enrolled vs. those not enrolled in the feeding assays ($P=0.92$, Table 1).

The proportion of gametocytes in isolates collected from recrudescence patients (Drec) were 17.9% by microscopy (5/28, median=40 gametocytes/ μ l range: 8-1823 gametocytes/ μ l) and 89.3% by RT-PCR (25/28). Blood samples from 12/28 recrudescence patients were tested for mosquito infection and only one patient (8.3%) was infectious. For this patient (PFPQD_002), infection prevalence and intensity were lower at Drec compared to D0 (prevalence 10 vs. 41.7%, 2.6 vs. 4.7 oocysts; Table S1). Among the six patients who experienced a second recrudescence, the proportion of gametocytes in isolates was 20% by microscopy (1/5, gametocyte density=80 gametocytes/ μ l) and 80% by RT-PCR (4/5). Blood samples from 5/6 recrudescence patients were tested for mosquito infection and none were infectious to mosquitoes (Table 1, Table S1).

Out of the 109 enrolled patients, the proportion of gametocyte carriers detected by RT-PCR on D0 samples was not significantly affected by the studied factors of sex ($P=0.98$), G6PD phenotype ($P=0.4$), age ($P=0.45$), seasonality ($P=0.067$), haemoglobinopathies ($P=0.11$), K13 alleles (44.1% for wild-type vs. 42.5% for mutant-type, $P=0.87$), and clinical outcome (cured vs. recrudescence, $P=0.83$). However, among the 28 recrudescence patients, the proportion of gametocyte carriers detected by RT-PCR increased significantly between D0 and Drec samples (46.4% vs. 89.3%, $P=0.0015$).

Additional symptomatic cohort

Fifteen additional patients with uncomplicated falciparum malaria were enrolled in 2016. *P. falciparum* gametocytes were detected in 2/15 patients (13.3%, 5 and 15,205 gametocytes/ μ l) by microscopy and in 7/15 patients (47%) by RT-PCR. Among the 14 patients enrolled in the feeding assays, only the patient with the highest gametocytemia (7.1%, 1/14) was found to be infectious to mosquitoes in both DMFA and SFA. The overall parasite prevalence in mosquitoes (DMFA and SFA) was higher for *An. minimus* (94%, 89/94) compared to *An. dirus* (71%, 71/100), whereas the mean number of oocysts was lower in *An. minimus* compared to *An. dirus* (184 vs. 210 respectively; Figure S2). These differences were still observed regardless of the feeding system: 94% (mean oocysts=171) for *An. minimus* vs. 60% (mean oocysts=106) for *An. dirus* using DMFA and 95.5% (mean oocysts=198) for *An. minimus* vs. 82% (mean oocysts=286) for *An. dirus* using the SFA.

Contribution to malaria transmission of asymptomatic parasite carriers

Follow-up during the dry season

The proportion of *Plasmodium* infections detected by RT-PCR was 12.2% (43/352), and did not differ significantly between febrile patients (16%, 12/75) and asymptomatic individuals (11.2%, 31/277, $P=0.35$). The distribution of the *Plasmodium* species was similar between the two groups (febrile group: 3 *P. falciparum*, 7 *P. vivax* and 2 mixed *P. falciparum/P. vivax*; asymptomatic group: 13 *P. falciparum*, 13 *P. vivax*, 3 mixed *P. falciparum/P. vivax* and 2 *P. malariae*).

DMFA and PCR analyses were carried out one week later from three malaria-free individuals (confirmed by RT-PCR) and 29 asymptomatic *Plasmodium* sp. carriers (all *P. falciparum*, *P. vivax*

and mixed *P. falciparum*/*P. vivax*). None were infectious to mosquitoes, except one *P. vivax* participant (58%, 3 ± 0.45 oocysts; Table 2, Table S2).

Among the 17 participants (13 *P. falciparum*, 1 *P. vivax*, 3 mixed *P. falciparum*/*P. vivax*) followed-up weekly for DMFA and PCR analyses until week 8 (Table S3), 5 became symptomatic: two in week 1, two in week 2 and one in week 3. Only one mixed *P. falciparum*/*P. vivax* participant who became symptomatic in week 2 was infectious to mosquitoes (1/50 fed mosquitoes, $2 \pm 4\%$, 1 oocyst, Table S3). One participant was lost to follow-up at week 5. Of the 11 participants who completed the two months follow-up (all were *P. falciparum* positive on week 0), none was infectious to mosquitoes overtime. The highest *P. falciparum* gametocyte density found by RT-PCR was 50 gametocytes/ μ l, regardless of the collection date (Table S3).

Follow-up during the rainy season.

Among the 706 villagers screened for *Plasmodium* infections, 36 (5.1%) were febrile ($>37.5^{\circ}\text{C}$) and 2 (0.28%) of them were RT-PCR positive for *P. vivax* and mixed *P. falciparum*/*P. vivax*. Among the 670 asymptomatic participants, 44 (6.6%) were found positive by RT-PCR (6 *P. falciparum*, 33 *P. vivax*, 4 mixed *P. falciparum*/*P. vivax*, 1 *P. malariae*). The proportion of asymptomatic carriers was significantly lower during the rainy season compared to the dry season (6.6% vs. 11.2%, $P=0.02$).

Post screening, 3 malaria-free individuals and 26 *Plasmodium* sp. carriers (6 *P. falciparum*, 15 *P. vivax*, 4 mixed *P. falciparum*/*P. vivax*, 1 *P. malariae* from week 0) were enrolled for serial DMFA and RT-PCR (Table S3). One *P. falciparum* asymptomatic participant became symptomatic in

week 1 without infecting mosquitoes. The three malaria-free individuals became positive during the follow-up. Except for two *P. vivax* asymptomatic participants, all individuals were not infectious to mosquitoes.

The first *P. vivax* participant was infectious in week 1 ($88\pm9\%$; 81.8 ± 5.8 oocysts), week 4 ($88\pm9\%$; 16 ± 1.25 oocysts) and week 6 ($78\pm11\%$; 21.3 ± 2.55 oocysts). While positive for a *P. falciparum*/*P. vivax* infection in week 1, the *P. falciparum* gametocyte RT-PCR was negative, supporting only *P. vivax* transmission. The second *P. vivax* asymptomatic participant was infectious in week 1 ($76\pm12\%$; 11.1 ± 1.4 oocysts), week 3 ($6\pm6.6\%$; 1 ± 0 oocyst) and week 6 ($31.6\pm13\%$; 1.8 ± 0.3 oocysts). The highest *P. falciparum* gametocyte density found by RT-PCR was 5 gametocytes/ μ l (Table S3).

Comparing the infectivity of asymptomatic and symptomatic parasite carriers

Of the 8 asymptomatic carriers infectious to mosquito (8/192; 0/52 *P. falciparum*, 2/56 *P. falciparum*/*P. vivax*, 6/84 *P. vivax*), $2.25\pm0.3\%$ (213/9458) mosquitoes became infected whereas $2.7\pm0.5\%$ (107/3933) mosquitoes fed on symptomatic carriers (5/79) became infected ($P=0.8$). The number of mosquitoes infected by *P. falciparum* asymptomatic carriers (0%, 0/2565) and *P. falciparum* symptomatic carriers ($2.7\pm0.5\%$, 107/3933) was not significantly different ($P=0.56$).

Discussion

Our study set out to characterize infectivity in patients attending local health centers and asymptomatic individuals in the community using both DFMA and SFA techniques and the two most important mosquito vectors in Cambodia, *An. minimus* and *An. dirus*. We found very low infectivity in the falciparum-infected patients at baseline (~6%) and on the day of treatment failure

(~8%) and the complete absence infectivity in *P. falciparum* asymptomatic carriers despite two months follow up in the wet and dry seasons. DMFA are usually strongly correlated with SFA techniques [7], however, their precision in carriers with low gametocytemias has been questioned [13]. On a subset of patients, both assays gave similar results reconfirming their good correlation [7] as well as a low infectivity rate of falciparum carriers and exclude a technical limitation in our hands.

Our low infectivity in patients is consistent with the work from Oddar Meanchey province (northwest Cambodia) in which an almost identical figure was observed, 5.9% of symptomatic carriers were infectious [17]. In contrast to *P. falciparum*, two *P. vivax* asymptomatic carriers were infectious to *An. dirus* mosquitoes that persisted over several weeks. RT-PCR quantified gametocytaemia in the *P. falciparum* asymptomatic carriers was low and this is probably the main cause of the low infectivity.

Although recent studies conducted in Pailin province (western Cambodia) observed that 16% of the population (n=1447) was malaria positive by using a high blood volume based molecular assay, the geometric mean parasite density was low, ~5 parasites/ μ l with an upper IQR of 5.5/ μ l; densities of $\geq 10,000$ μ l were observed in the 90th centile and above [27, 28]. We also found low densities of *P. falciparum* gametocytes in asymptomatic carriers but our highest gametocytemia was only 50 gametocytes/ μ l, which did not increase over time. Our finding a tight distribution of gametocyte densities in the asymptomatic carriers is more concordant with data from low transmission areas of Ethiopia [29] compared to the low transmission areas of Pailin, Thailand and Vietnam [27, 28].

Surprisingly we observed a significantly higher proportion of asymptomatic carriers in the dry season (~11%) compared to the rainy season (~7%). One hypothesis could be that *P. falciparum* parasites in low-transmission area have been selected to limit their commitment toward reproductive stages during the dry season when few vectors are present, and asexual stages are capable of surviving at low densities in the human host. By contrast, the rainy season offers increased transmission opportunities so multiplication rates of asexual stages may increase leading to increased gametocytogenesis. Previous reports have shown that *P. falciparum* strains are able to modulate their transmission strategy according to the environmental context [30-34].

We also observed the long-term carriage of monoclonal infection in most asymptomatic carriers (Table S4) suggesting that the ability of the host immune system to control falciparum infections at very low densities might be even further selected by the low genetic diversity [35, 36]. However, when immunity fails, breakthrough clinical episodes occur, which we observed for five asymptomatic carriers during the dry season. More research is needed in low transmission areas to decipher the capacity of *P. falciparum* parasites to adapt its transmission strategy and determine which internal and external factors might trigger it (seasonality, waning immunity, vector presence, new infecting strains etc.).

Our findings highlight the need to consider carefully optimal elimination strategies in our setting where the majority of malaria cases occurs in young adults who work in the forests. Our study and that of Lin *et al.* [17] show that infectivity is greater in symptomatic patients. Accordingly, the prompt detection and treatment of *P. falciparum* patients with an effective antimalarial drug against asexual parasites and the rapid implementation of adding SLDPQ without the need to screen for

G6PD deficiency are essential elements of an elimination strategy for Cambodia. We assessed infectivity in 55 asymptomatic carriers and 6 malaria-free individuals among whom only 46 participants were followed over time. However, the very low infectivity of these carriers hampered our ability to statistically assess their contribution to malaria transmission. Consequently, more data in this important group in other low transmission areas of SE Asia are needed, especially near transmission hot spots like forests.

To conclude, we have demonstrated low infectivity in both symptomatic patients and asymptomatic carriers, but were under powered to show a statistically significant difference between the two groups. We reconfirm the high failure rate of DHA-PP and its associated high gametocyte prevalence. More infectivity data would support optimal elimination strategies between symptomatic and asymptomatic malaria reservoirs but in the interim SLDPQ should be deployed to support malaria elimination efforts in patients.

Conflicts of interest. All authors declare no conflicts of interest.

Funding. This work was supported by the Institut Pasteur in Cambodia, FEI 5% initiative (grant number 12INI211, ‘Towards malaria elimination: effective strategies against transmission. The new challenges in South East Asia’), Rotary Club (grant number GG1523934, ‘Amélioration des capacités en entomologie des acteurs luttant contre le paludisme et de de la compréhension de la transmission du paludisme’), USAID / PMI / CDC through Malaria Consortium (‘The tolerability and safety of low dose primaquine for transmission blocking in symptomatic falciparum infected

Cambodians') and Dedonder Clayton (grant number EC/MAM/N°325/14). AV was supported by a post-doctoral fellowship from the International Direction, Institut Pasteur, Paris, France.

Corresponding author contact information: Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, 5 Monivong Bd, 12201 Phnom Penh, PO983, Cambodia. Email: amelie.vantaux@gmail.com

References

1. World Health Organization. World malaria report 2016. Licence: CC BY-NC-SA 3.0 IGO ed. Vol. Volume WHO/HTM/GM, **2016**:186.
2. Noedl H, Se Y, Schaecher K, et al. Evidence of Artemisinin-Resistant Malaria in Western Cambodia. *N Engl J Med* **2008**; 359:2619-20.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* **2009**; 361.
4. Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisinin-piperaquine failure in Cambodia. *N Engl J Med* **2014**; 371:484-5.
5. Leang R, Taylor WR, Bouth DM, et al. Evidence of *Plasmodium falciparum* malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. *Antimicrob Agents Chemother* **2015**; 59:4719-26.
6. Leang R, Khu NH, Mukaka M, et al. An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. *BMC Med* **2016**; 14:171.

392 7. Bousema T, Dinglasan RR, Morlais I, et al. Mosquito feeding assays to determine the
393 infectiousness of naturally infected *Plasmodium falciparum* gametocyte carriers. PLoS ONE
394 **2012**; 7:e42821.

395 8. Bousema T, Churcher TS, Morlais I, Dinglasan RR. Can field-based mosquito feeding assays
396 be used for evaluating transmission-blocking interventions? Trends Parasitol **2013**; 29:53-9.

397 9. Jeffery GM, Eyles DE. Infectivity to mosquitoes of *Plasmodium falciparum* as related to
398 gametocyte density and duration of infection. Am J Trop Med Hyg **1955**; 4:781-9.

399 10. Churcher TS, Bousema T, Walker M, et al. Predicting mosquito infection from *Plasmodium*
400 *falciparum* gametocyte density and estimating the reservoir of infection. eLife **2013**; 2:e00626.

401 11. Coleman RE, Kumpitak C, Ponlawat A, et al. Infectivity of asymptomatic *Plasmodium*-
402 infected human populations to *Anopheles dirus* mosquitoes in Western Thailand. J Med Entomol
403 **2004**; 41:201-8.

404 12. Schneider P, Bousema JT, Gouagna LC, et al. Submicroscopic *Plasmodium falciparum*
405 gametocytes densities frequently result in mosquito infection. Am J Trop Med Hyg **2007**;
406 76:470-4.

407 13. Gaye A, Bousema T, Libasse G, et al. Infectiousness of the human population to *Anopheles*
408 *arabiensis* by direct skin feeding in an area hypoendemic for malaria in Senegal. Am J Trop Med
409 Hyg **2015**; 92:648-52.

410 14. Sattabongkot J, Maneechai N, Phunkitchar V, et al. Comparison of artificial membrane
411 feeding with direct skin feeding to estimate the infectiousness of *Plasmodium vivax* gametocytes
412 carriers to mosquitoes. Am J Trop Med Hyg **2003**; 69:529-35.

413 15. Pethleart A, Prajakwong S, Suwonkerd W, Corthong B, Webber R, Curtis C. Infectious
414 reservoir of *Plasmodium* infection in Mae Hong Son Province, north-west Thailand. *Malar J*
415 **2004**; 3:34.

416 16. Kiattibutr K, Roobsoong W, Sriwichai P, et al. Infectivity of symptomatic and asymptomatic
417 *Plasmodium vivax* infections to a Southeast Asian vector, *Anopheles dirus*. *Int J Parasitol* **2017**;
418 47:163-70.

419 17. Lin JT, Ubalee R, Lon C, et al. Microscopic *Plasmodium falciparum* gametocytemia and
420 infectivity to mosquitoes in Cambodia. *J Infect Dis* **2016**; 213:1491-4.

421 18. Sluydts V, Heng S, Coosemans M, et al. Spatial clustering and risk factors of malaria
422 infections in Ratanakiri Province, Cambodia. *Malar J* **2014**; 13:387.

423 19. Coosemans M, Van Bortel W. Malaria vectors in the Mekong Countries: a complex
424 interaction between vectors, environment and human behaviour. In: Proceedings of the
425 International Conference Hubs Harbours and Deltas in Southeast Asia.6-8.

426 20. Canier L, Khim N, Kim S, et al. An innovative tool for moving malaria PCR detection of
427 parasite reservoir into the field. *Malar J* **2013**; 12:405.

428 21. Lawaly YR, Sakuntabhai A, Marrama L, et al. Heritability of the Human Infectious Reservoir
429 of Malaria Parasites. *PLOS ONE* **2010**; 5:e11358.

430 22. Arieu F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant
431 *Plasmodium falciparum* malaria. *Nature* **2014**; 505:50-5.

432 23. Daniels R, Volkman SK, Milner DA, et al. A general SNP-based molecular barcode for
433 *Plasmodium falciparum* identification and tracking. *Malar J* **2008**; 7:223.

434 24. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of
435 artemisinin-resistant *Plasmodium falciparum* malaria in Cambodia: in-vitro and ex-vivo drug-
436 response studies. *Lancet Infect Dis* **2013**; 13:1043-9.

437 25. Khim N, Benedet C, Kim S, et al. G6PD deficiency in *Plasmodium falciparum* and
438 *Plasmodium vivax* malaria-infected Cambodian patients. *Malar J* **2013**; 12:171.

439 26. Crawley MJ. The R book. The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ,
440 England: John Wiley & Sons Ltd, **2007**.

441 27. Imwong M, Nguyen T, Tripura R, et al. The epidemiology of subclinical malaria infections in
442 South-East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas,
443 Cambodia, and Vietnam. *Malar J* **2015**; 14:381.

444 28. Imwong M, Stepniewska K, Tripura R, et al. Numerical distributions of parasite densities
445 during asymptomatic malaria. *J Infect Dis* **2016**; 213:1322-9.

446 29. Tadesse FG, van den Hoogen L, Lanke K, et al. The shape of the iceberg: quantification of
447 submicroscopic *Plasmodium falciparum* and *Plasmodium vivax* parasitaemia and
448 gametocytaemia in five low endemic settings in Ethiopia. *Malar J* **2017**; 16:99.

449 30. Dyer M, Day KP. Commitment to gametocytogenesis in *Plasmodium falciparum*. *Parasitol*
450 *Today* **2000**; 16:102-7.

451 31. Talman AM, Domarle O, McKenzie FE, Arieu F, Robert V. Gametocytogenesis : the puberty
452 of *Plasmodium falciparum*. *Malar J* **2004**; 3:24.

453 32. Buckling AGJ, Taylor LH, Carlton JMâR, Read AF. Adaptive changes in *Plasmodium*
454 transmission strategies following chloroquine chemotherapy. *Proc R Soc B* **1997**; 264:553-9.

455 33. Buckling A, Ranford-Cartwright LC, Miles A, Read AF. Chloroquine increases *Plasmodium*
456 *falciparum* gametocytogenesis in vitro. *Parasitology* **1999**; 118:339-46.

- 457 34. Gadalla AAH, Schneider P, Churcher TS, et al. Associations between season and gametocyte
458 dynamics in chronic *Plasmodium falciparum* infections. PLOS ONE **2016**; 11:e0166699.
- 459 35. Douglas AD, Andrews L, Draper SJ, et al. Substantially reduced pre-patent parasite
460 multiplication rates are associated with naturally acquired immunity to *Plasmodium falciparum*.
461 J Infect Dis **2011**; 203:1337-40.
- 462 36. Ofosu-Okyere A, Mackinnon MJ, Sowa MP, et al. Novel *Plasmodium falciparum* clones and
463 rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian
464 children during the transition into the high transmission season. Parasitology **2001**; 123:113-23.
- 465
- 466

467 **Figure legend**

468 **Figure 1.** Schematic design of the symptomatic and asymptomatic studies.

Table 1. Characteristics of the symptomatic *Plasmodium falciparum* patients enrolled in Rattanakiri province, Cambodia 2015-2016. SLDPQ study represents the individuals enrolled in the open-label randomised control trial assessing the tolerability and the safety of SLDPQ while the second study represents the additional symptomatic cohort from 2016. Drec1 and Drec2 correspond to Day 0 sampling of the first and second recrudescences, respectively.

Study	Case	Number	Mean age, yrs (SD)	Number of gametocyte positive slide	Mean gameto-cytemia/ μ l (SD, range)	Number of positive gametocyte RT-PCR	Infectivity
<i>SLDPQ</i>							
	D0 (feeds)	48	26 (15)	8 (16.7%)	71 (254, 0-1432)	20 (41.7%)	6.2%
	D0 (no feed)	61	24 (14)	13 (21%)	36 (142, 0-800)	26 (43%)	NA
	Drec1 (feeds)	12	24 (14)	2 (17%)	161 (524, 0-1883)	10 (83%)	8.3%
	Drec1 (no feed)	16	19 (10)	2 (12.5%)	3 (10, 0-40)	15 (94%)	NA
	Drec2 (feeds)	5	20 (15)	1 (20%)	16 (36, 0-80)	3/4 (75%)	0
	Drec2 (no feed)	1	10	NA	NA	NA	NA
<i>Additional cohort</i>							
	D0 (feeds)	14	20 (10)	2 (14.3%)	1086 (4063, 0-15,205)	7 (50%)	7.1%
	D0 (no feed)	1	54	0	0	1	NA

Table 2. Characteristics of the asymptomatic participant's follow-ups carried out in the dry and the rainy season in Rattanakiri province, Cambodia 2016.

Season	Number of participants	Number of feeds	Number of falciparum positive gametocyte RT-PCR	Infectivity
Dry	32	91	71.7% (43/60)	2.2% (2/91)
Rainy	29	168	49 % (27/55)	3.6% (6/168)